Compare HIHO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | CANF |
|---|---|---|
| Founded | 1990 | 1994 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.0M |
| IPO Year | 1996 | N/A |
| Metric | HIHO | CANF |
|---|---|---|
| Price | $1.18 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 9.1K | ★ 19.3M |
| Earning Date | 01-20-2026 | 11-27-2025 |
| Dividend Yield | ★ 10.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $7,080,000.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $117.00 | ★ N/A |
| Revenue Growth | ★ 3.31 | N/A |
| 52 Week Low | $1.12 | $0.28 |
| 52 Week High | $2.05 | $2.35 |
| Indicator | HIHO | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 23.94 | 47.65 |
| Support Level | $1.12 | $0.28 |
| Resistance Level | $1.17 | $0.36 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 14.45 | 32.09 |
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).